Inhibrx Announces Chiesi Farmaceutici S.p.A declined to exercise its option for ex-North America Rights To Develop And Commercialise INBRX-101
Portfolio Pulse from Benzinga Newsdesk
Inhibrx has announced that Chiesi Farmaceutici S.p.A has declined to exercise its option for ex-North America rights to develop and commercialise INBRX-101.
September 19, 2023 | 8:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Inhibrx's partner, Chiesi Farmaceutici, has declined to exercise its option for ex-North America rights to INBRX-101. This could potentially impact Inhibrx's future revenues and global expansion plans.
Chiesi Farmaceutici's decision not to exercise its option for ex-North America rights to INBRX-101 could limit Inhibrx's ability to generate revenue from this drug outside North America. This could negatively impact Inhibrx's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100